Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Phase 4 Interventional Results available

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

NCT00984659
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone propionate/salmeterol combination product, Salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Jasper, Alabama • Mobile, Alabama • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 15, 2026, 7:36 AM EDT
Terminated Not applicable Interventional Results available

N-Acetylcysteine for Patients With COPD and Chronic Bronchitis

NCT01739790
View directory record Official record
Conditions
COPD, Chronic Bronchitis
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 15, 2026, 7:36 AM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

NCT00992680
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ROX Anastomotic Coupler System (ACS)
Device
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Prospective Study Comparing Different Modalities of Oxygen Delivery During Assessment of Functional Exercise Capacity

NCT00484562
View directory record Official record
Conditions
COPD
Interventions
Standard oxygen delivery system, Homefill oxygen delivery system, Helios oxygen delivery system, FreeStyle oxygen system
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Home Air Purification for Eosinophilic COPD

NCT04252235
View directory record Official record
Conditions
COPD, Eosinophilia
Interventions
Air purifier, Sham air purifier
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust

NCT03089515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lower Respiratory Disease
Interventions
Cardio-Pulmonary Exercise Testing (CPET)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 15, 2026, 7:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium

NCT02056158
View directory record Official record
Conditions
HIV, COPD, Emphysema, Smoking
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 15, 2026, 7:36 AM EDT
Recruiting Not applicable Interventional

PEP Buddy in Pulmonary Rehabilitation

NCT07404826
View directory record Official record
Conditions
COPD
Interventions
PEP Buddy, PEP Buddy Sham
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 15, 2026, 7:36 AM EDT
Completed No phase listed Observational

Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center

NCT00870857
View directory record Official record
Conditions
HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 15, 2026, 7:36 AM EDT
Completed No phase listed Observational

Pneumocystis in Pathogenesis of HIV-associated Emphysema

NCT00869544
View directory record Official record
Conditions
HIV Infections, Pneumocystis Pneumonia, Emphysema, Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

NCT05830071
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants

NCT02612389
View directory record Official record
Conditions
Pulmonary Disease, Autonomic Dysfunction, COPD
Interventions
Meditative Movement taught via DVD
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 15, 2026, 7:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)

NCT01099410
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fiberoptic bronchoscopy, blood draw, intravenous catheter
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 15, 2026, 7:36 AM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

NCT01321463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 15, 2026, 7:36 AM EDT
Completed No phase listed Observational

Making Sense of Dyspnea Assessment

NCT02771262
View directory record Official record
Conditions
COPD, Dyspnea
Interventions
Pulmonary Rehabilitation
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 15, 2026, 7:36 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

NCT00726479
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 15, 2026, 7:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039
View directory record Official record
Conditions
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 7:36 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 15, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 15, 2026, 7:36 AM EDT